Real-World Clinical Outcomes for Prostate Cancer Patients with Biochemical Recurrence

A US-based retrospective observational study of 26,755 patients with non-metastatic prostate cancer, using the Optum® PC electronic medical record database. It assesses biochemical recurrence rates and clinical outcomes, including metastasis and castration-resistant PC, based on prostate-specific antigen doubling time. The dataset was authored by Neal D. Shore and last updated on 2026-04-29.

Use Cases

• Predicting the risk of metastasis based on PSA doubling time and treatment cohort.
• Analyzing time-to-event outcomes such as time from biochemical recurrence to castration-resistant prostate cancer.
• Comparing clinical outcomes between high-risk and low-risk biochemical recurrence groups after different local therapies.
• Modeling the association between baseline patient characteristics and time to biochemical recurrence.

Strengths

• Large patient cohort of 26,755 individuals from a US electronic medical record database.
• Provides specific outcome percentages, such as 19.7% of patients experiencing biochemical recurrence after radical prostatectomy.
• Distinguishes between high-risk and low-risk groups based on a clinically relevant PSA doubling time threshold of 12 months.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic and temporal bias inherent to the source database and study period.

Provenance

Source

Optum® PC electronic medical record database.

Collection Method

Retrospective observational study.

Freshness

Last updated 2026-04-29 11:20:21; freshness should be verified.

Geography

United States